Corneal Ulcer - Pipeline Insight, 2024

This “Corneal Ulcer - Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Corneal Ulcer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Corneal Ulcer Understanding

Corneal Ulcer: Overview

A Corneal Ulcer (also known as keratitis) is an open sore on the cornea. The cornea covers the iris and the round pupil, much like a watch crystal covers the face of a watch. A corneal ulcer usually results from an eye infection, but severe dry eye or other eye disorders can cause it.

A corneal ulcer, a defect of the corneal epithelium involving the underlying stroma, is a potentially vision-threatening ocular emergency. Even with prompt treatment patients can suffer significant morbidity with complications including corneal scarring or perforation, development of glaucoma, cataracts or anterior and posterior synechiae, and vision loss. Untreated bacterial keratitis may result in endophthalmitis and subsequent loss of the eye.

Symptoms
Symptoms of corneal ulcers include:

• Redness of the eye
• Severe pain and soreness of the eye
• The feeling of having something in eye
• Tearing
• Pus or other discharge
• Blurred vision
• Sensitivity to light
• Swelling of the eyelids
• A white spot on cornea that may or may not be able to see when looking in the mirror

Diagnosis
The ophthalmologist will use a special dye called fluorescein (pronounced FLOR-uh-seen) to light up any damage to cornea. They will then examine your cornea using a special microscope called a slit lamp. The slit-lamp exam will allow your ophthalmologist to see the damage to your cornea and determine if the patient have a corneal ulcer.

Treatment
Antibiotic, antifungal or antiviral eye drops are the treatments of choice. Sometimes ophthalmologist will prescribe antifungal tablets. In other cases, they will treat with an injection of medication near the eye. steroid or anti-inflammatory eye drops may also be prescribed after infection has improved or is gone

Corneal Ulcer Emerging Drugs Chapters

This segment of the Corneal Ulcer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Corneal Ulcer Emerging Drugs

Poliesanide: Sifi S.p.APoliesanide is being developed by Sifi for the treatment of Acanthamoeba Keratitis. It is currently in phase III stage of development.

CODA001: Ocu Nexus Therapeutics CODA001 is an antisense oligonucleotide that down regulates the expression of the gap junction protein Cx43 which is increased in persistent epithelial defects. The first use in patients with persistent epithelial defects was reported by Ormonde et al. Five eyes with severe ocular surface burns, which were unresponsive to established therapy, were treated by connexin43-specific antisense oligodeoxynucleotide delivered in cold, thermo reversible Poloxamer407 gel under either amniotic membrane graft or bandage contact lens. The treatment reduced inflammation within 1-2 days, and complete corneal reepithelialization was obtained in all eyes. The drug was initially being developed by CODA therapeutics and after the acquisition OcuNexus Therapeutics is further developing the drug in phase II stage ofdevelopment.

Synthetic inhibitors of fibroblast growth factor (FGF): Dobecure Dobecure is working on preclinical and clinical studies in disorders where the synthetic inhibitors of fibroblast growth factor (FGF) might be involved, such us age-related macular degeneration, both wet and dry, uveitis, corneal edema and herpetic Keratitis, tendinitis and tendinosis, cold sores, otitis and allergic rhinitis. As per the company pipeline, it is currently in Phase I stage ofdevelopment.

TTHX1114: Trefoil Therapeutics TTHX1114 eye drops to reduce the duration and impact of ocular, herpes virus related ulcers (herpetic keratopathy), and other corneal ulcers. Trefoil is developing a topical (eye drop) version of TTHX1114 for herpes-induced corneal ulcers to accelerate corneal wound healing, stimulate epithelial cell growth and reduce complications such as pain and inflammation. Topical TTHX1114 has potential to complement the use of other treatments for the underlying infection, such as antiviral drugs and surgery. In preclinical studies, the TTHX1114 significantly reduced corneal damage in animal models of herpetic keratopathy. The topical formulation is expected to enter clinical trials in 2021.

Corneal Ulcer: Therapeutic Assessment

This segment of the report provides insights about the different Corneal Ulcer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Corneal Ulcer

There are approx. 15+ key companies which are developing the therapies for Corneal Ulcer. The companies which have their Corneal Ulcer drug candidates in the most advanced stage, i.e. phase III include Sifi S.p.A and others

Phases

This report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Corneal Ulcer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Corneal Ulcer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III II, I, preclinical and discovery stage. It also analyses Corneal Ulcer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Corneal Ulcer drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Corneal Ulcer R&D. The therapies under development are focused on novel approaches to treat/improve Corneal Ulcer.

• Trefoil has licensed patents from Florida State University covering TTHX1114 as well as its use in ophthalmic conditions. Trefoil supplemented these patents with filings on company-developed technology.
• In March 2016, Eyegate Pharmaceuticals acquired Jade Therapeutics. Jade’s proprietary, cross-linked, bio-erodible hydrogel technology has demonstrated a variety of unique and beneficial characteristics, whether employed alone or as a sustained-release drug-delivery vehicle.
• In December 2018, Recordati announced that the FDA has granted orphan drug designation to Recordati Rare Disease’s investigational product REC 0559 for the treatment of neurotrophic keratitis.

Corneal Ulcer Report Insights

• Corneal Ulcer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Corneal Ulcer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Corneal Ulcer drugs?
• How many Corneal Ulcer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Corneal Ulcer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Corneal Ulcer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Corneal Ulcer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Ocu NexusTherapeutics
• Recordati Rare Diseases
• Santen S.A.S.
• First StringResearch
• Regeneratetx
• Stuart Therapeutics
• Eye GatePharmaceuticals
• Trefoil Therapeutics
• Ameba GoneInc
• Dobecure
• Editas medicine

Key Products

• CODA001
• REC 0559
• Ciclosporin emulsion
• ACT1
• REG-001
• ST-100
• CMHA-S gel
• TTHX1114
• Research program for Bacterial keratitis
• Synthetic inhibitors of fibroblast growth factor (FGF)
• CRISPR/CAS9 gene editing

This product will be delivered within 2 business days.